Pursuant to Provisions of Regulation 33 read with Regulation 30 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jubilant Pharmova has informed that the Board of Directors of the Company has, at its meeting held today, on Monday, May 29, 2023 considered and approved the Audited Standalone and Consolidated Financial Statement of the Company for the quarter and Financial Year ended March 31 2023.
The above information is a part of company’s filings submitted to BSE.
